Top

Published in:

01-08-2008 | Gastrointestinal Oncology

7-Year Survival Results of Perioperative Chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP) in Locally Advanced Resectable Gastric Cancer: Up-to-date Analysis of a Phase-II Study

Authors: Roberto Persiani, MD, Stefano Rausei, MD, Carmelo Pozzo, MD, Alberto Biondi, MD, Carlo Barone, MD, Ferdinando C. M. Cananzi, MD, Giovanni Schinzari, MD, Domenico D’Ugo, MD, FACS

Published in: Annals of Surgical Oncology | Issue 8/2008

Abstract

Background

Perioperative chemotherapy is considered an effective treatment option for patients with gastric carcinoma. We report the results after a 7-year follow-up of a study aimed at evaluating a perioperative chemotherapy protocol in a group of patients with locally advanced gastric cancer (LAGC).

Methods

Between February 1996 and May 2000, 24 patients with LAGC underwent D2-gastrectomy after three preoperative cycles of chemotherapy (Epidoxorubicin, Etoposide, Cisplatinum). Three further cycles were planned after surgery. Differences among groups were evaluated using the chi-square test. Survival rate was calculated after a 7-year follow-up, and differences were assessed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model.

Results

A total of 24 patients received preoperative chemotherapy and underwent surgical resection. Of these, 17 (71%) received postoperative treatment. The main toxicity was grade 3–4 neutropenia. Curative resection (R0) was achieved in 83.3% of patients. No pathologic complete responses were documented, but tumor downstaging was obtained in 10 of 24 patients (41.7%). Overall median survival was 40 months, and 7-year survival rate was 46%. At univariate and multivariate analysis, R0 resection and tumor diameter were the most important prognostic factors.

Conclusion

Long-term results in our series show a survival benefit for LAGC patients treated by perioperative chemotherapy and D2-gastrectomy when compared with previously studied controls who had surgery with postoperative chemotherapy alone. The high rate and prognostic impact of R0 resection in this study stressed the role of the therapy during the preoperative phase.

Kobayashi T, Kimura T. Long-term outcome of preoperative chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. Jpn J Cancer Chemother 2000; 27:1521–6

Schuhmacher CP, Fink U, Becker K. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 91:918–27PubMedCrossRef

Marcus SG, Cohen D, Lin K, et al. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg 2003; 7:1015–22PubMedCrossRef

Hartgrink HH, van deVelde CJH, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial INCLUDE. Eur J Surg Oncol 2004; 30:643–9PubMedCrossRef

Nio Y, Koike M, Omori H, et al. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study. Anticancer Res 2004; 24:1879–87PubMed

Wu AW, Xu GW, Wang HY, et al. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005047. doi:10.1002/14651858.CD005047.pub3

Cunningham D, Allum WH, Stenning SP, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20PubMedCrossRef

Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5PubMedCrossRef

Barone C, Cassano A, Pozzo C, et al. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Oncology 2004; 67:48–53PubMedCrossRef

10.

Picciocchi A, D’Ugo DM, Ronconi P, et al. The impact of staging laparoscopy on the treatment of locally advanced gastric cancer. J Exp Clin Cancer Res 1997; 16:84–6

11.

Barone C, Corsi DC, Pozzo C, et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer 1998; 82:1460–7PubMedCrossRef

12.

World Health Organisation: “Handbook for Reporting Results for Cancer Treatment.” Geneva: WHO, 1979

13.

Japanese Research Committee for Gastric Cancer: The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981; 11:127–38CrossRef

14.

Sobin LH, Wittekind C. “TNM classification of malignant tumors, 6th edition.” New York: John Wiley & Sons, 2002

15.

Becker K, Fumagalli U, Mueller JD, et al. Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma: effect on tumor cell microinvolvement of regional lymph nodes. Cancer 1999; 85:1484–9PubMedCrossRef

16.

Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten-Year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449–61PubMedCrossRef

17.

Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991; 67[Suppl 1]:260–5PubMedCrossRef

18.

Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7:1310–7PubMed

19.

Bajetta E, Di Bartolomeo M, de Braud F, et al. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. Eur J Cancer 1994; 30A:596–600PubMedCrossRef

20.

Diaz-Rubio E, Jimeno J, Aranda E, et al. Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.). Ann Oncol 1992; 3:861–3PubMed

21.

Clark JL, Kucuk O, Neuberg DS, et al. Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18:318–24PubMedCrossRef

22.

D’Ugo D, Persiani R, Rausei S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol 2006; 32:1105–9PubMedCrossRef

23.

Yonemura Y, Kinoshita K, Fujimura T, et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 1996; 43:1260–72PubMed

24.

Lowy AM, Mansfield PF, Leach SD, et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229:303–8PubMedCrossRef

25.

Becker K, Mueller JD, Schuhmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98:1521–30PubMedCrossRef

26.

Persiani R, D’Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol 2005; 89:227–36PubMedCrossRef

27.

Lim L, Michael M, Mann GB, et al. Adjuvant therapy in gastric cancer. J Clin Oncol 2005; 23:6220–32PubMedCrossRef

28.

Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006; 12:204–13PubMed

Title: 7-Year Survival Results of Perioperative Chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP) in Locally Advanced Resectable Gastric Cancer: Up-to-date Analysis of a Phase-II Study
Authors: Roberto Persiani, MD
Stefano Rausei, MD
Carmelo Pozzo, MD
Alberto Biondi, MD
Carlo Barone, MD
Ferdinando C. M. Cananzi, MD
Giovanni Schinzari, MD
Domenico D’Ugo, MD, FACS
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-9982-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

7-Year Survival Results of Perioperative Chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP) in Locally Advanced Resectable Gastric Cancer: Up-to-date Analysis of a Phase-II Study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2008

Which Is the Optimal Risk Stratification System for Surgically Treated Localized Primary GIST? Comparison of Three Contemporary Prognostic Criteria in 171 Tumors and a Proposal for a Modified Armed Forces Institute of Pathology Risk Criteria

Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer

Impact of Body Mass Index on Perioperative Outcomes in Patients Undergoing Major Intra-abdominal Cancer Surgery

Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion

Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer

Surgical Management and Prognostic Factors of Hilar Cholangiocarcinoma: Experience with 115 Cases in China